The thiol-disulfide homeostasis and coenzyme Q10 in conjunction with vitamin e effect on retinopathy prematurity


Creative Commons License

Akdogan M., ÜSTÜNDAĞ Y., Akdağ A., NEŞELİOĞLU S., EREL Ö.

Open Ophthalmology Journal, cilt.13, sa.1, ss.23-28, 2019 (Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 13 Sayı: 1
  • Basım Tarihi: 2019
  • Doi Numarası: 10.2174/1874364101913010023
  • Dergi Adı: Open Ophthalmology Journal
  • Derginin Tarandığı İndeksler: Scopus
  • Sayfa Sayıları: ss.23-28
  • Anahtar Kelimeler: Antioxidants, Coenzyme Q10, Retinopathy of Prematurity, Thiol, Vitamin E, FRAP
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Purpose: This study was performed to determine whether one drop of topical administration of Coqun® (Coenzyme Q10 and Vitamin E)-a potent antioxidant-twice a day has any effect on the thiol-disulphide homeostasis-a novel oxidative stress marker in the Retinopathy Of Prematurity (ROP) disease course. Methods: This was a prospective observational study comprising 28 infants with ROP at stage 2 and higher who followed up at the paediatric intensive care unit. Ferric reducing power of plasma (FRAP), albumin, ischemia-modified albumin (IMA) and thiol disulphide homeostasis levels were studied in the infants before and two weeks after Coqun® treatment. Results: The mean gestational age was 27 (24–32) weeks, the mean birth weight was 1,012±326 g and the mean duration of care in an incubator was 64±23 days. FRAP levels were 0.91±0.17 μmol/L, IMAs were 0.85±0.29, native thiols were 248±38.9 μmol/L and total thiols were 284±39.2 μmol/L, respectively, at the beginning of therapy. FRAP levels 0.79±0.21(p= 0.006) μmol/L, IMAs 0.73±0.36(p = 0.096), native thiols 262±42.6(p = 0.164) μmol/L and total thiols 291±43.6(p = 0.344) μmol/L showed no difference after two weeks of therapy. Conclusion: Thiol disulphide homeostasis levels do not change with Coqun® therapy during ROP course.